利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.037 秒)

    Remedy for corneal failure
    3.
    发明申请
    Remedy for corneal failure 审中-公开
    角膜失败的补救措施

    公开(公告)号：US20060234922A1

    公开(公告)日：2006-10-19

    申请号：US10533115

    申请日：2003-10-22

    申请人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Jun Inoue ,  Mitsuyoshi Azuma

    发明人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Jun Inoue ,  Mitsuyoshi Azuma

    IPC分类号： A61K31/4545 ,  A61K31/454 ,  A61K38/12 ,  A61K38/10

    CPC分类号： A61K38/31 ,  A61K31/00

    摘要： The present invention provides a new type of pharmaceutical agent that recovers corneal sensitivity after corneal surgery or improves the condition of dry eye. Application of a somatostatin receptor agonist is expected to provide an improvement effect on decreased corneal sensitivity after cataract surgery or LASIK surgery, decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like.

    摘要翻译： 本发明提供了在角膜手术后恢复角膜敏感性或改善干眼症状的新型药剂。 预期生长抑素受体激动剂的应用对于白内障手术或LASIK手术后的角膜敏感性降低，与角膜神经变性如神经麻痹性角膜病，角膜溃疡，糖尿病性角膜病等相关的角膜敏感性和干眼症的降低有改善作用。

    Agent for repairing corneal perception
    6.
    发明申请
    Agent for repairing corneal perception 审中-公开
    修复角膜感知的代理

    公开(公告)号：US20070093513A1

    公开(公告)日：2007-04-26

    申请号：US10553320

    申请日：2004-04-16

    申请人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Jun Inoue ,  Mitsuyoshi Azuma

    发明人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Jun Inoue ,  Mitsuyoshi Azuma

    IPC分类号： A61K31/517 ,  A61K31/454

    CPC分类号： A61K38/45 ,  A61K31/454 ,  A61K31/517 ,  C12Y304/22054

    摘要： The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like, since it contains a Rho protein inhibitor.

    摘要翻译： 本发明提供了用于在角膜手术后恢复角膜敏感性并改善干眼症状的新型药剂。 该药剂可用于改善与角膜神经变性相关的角膜敏感性和干眼症，如白内障术后，LASIK术后，PRK后术后，角膜内成形术，神经麻痹性角膜病，角膜溃疡，糖尿病性角膜病等。 它含有Rho蛋白抑制剂。

    Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative
    7.
    发明申请
    Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative 审中-公开
    包含Pacap及其衍生物的角膜神经发生启动子

    公开(公告)号：US20110212899A1

    公开(公告)日：2011-09-01

    申请号：US11578796

    申请日：2005-04-21

    申请人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Yutaka Inoue ,  Chiho Yabuta ,  Mitsuyoshi Azuma ,  Satomi Onoue

    发明人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Yutaka Inoue ,  Chiho Yabuta ,  Mitsuyoshi Azuma ,  Satomi Onoue

    IPC分类号： A61K38/17 ,  A61P27/02

    CPC分类号： A61K38/2278

    摘要： It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal sensitivity and corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in corneal sensitivity accompanying therewith.

    摘要翻译： 旨在提供用于促进包含PACAP，PACAP衍生物或其药学上可接受的盐的角膜神经发生的药剂，特别是用于促进角膜神经突发生的药物，其目的在于改善角膜敏感性，治疗干眼症并治疗角膜上皮损伤 促进角膜神经发生的作用。 用于促进角膜神经发生的药物可用作改善角膜手术如角膜手术（LASIK）和角膜移植术或白内障手​​术后角膜敏感性降低的药物，伴随角膜神经变性和干眼症状以及角膜上皮损伤伴随的角膜敏感性降低 角膜敏感度降低。 此外，它可用作改善干眼症状，减少干眼症患者的角膜敏感性和角膜上皮损伤的药物，以及用于改善角膜上皮损伤和干眼症状以及与之伴随的角膜敏感性降低的药物。

    Angiogenesis inhibitor
    8.
    发明授权
    Angiogenesis inhibitor 失效
    血管生成抑制剂

    公开(公告)号：US06214800B1

    公开(公告)日：2001-04-10

    申请号：US09282501

    申请日：1999-04-09

    申请人： Chiho Fukiage ,  Mitsuyoshi Azuma ,  Jun Inoue ,  Masayuki Nakamura ,  Yuka Yoshida

    发明人： Chiho Fukiage ,  Mitsuyoshi Azuma ,  Jun Inoue ,  Masayuki Nakamura ,  Yuka Yoshida

    IPC分类号： A61K3800

    CPC分类号： A61K38/55 ,  C07C311/19 ,  C07D303/48

    摘要： An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) and compounds of the formula (VI) can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

    摘要翻译： 一种包含半胱氨酸蛋白酶抑制化合物的血管生成抑制剂。 作为优选的半胱氨酸蛋白酶抑制化合物，可以使用环氧琥珀酸化合物，肽卤代酰肼化合物，钙蛋白酶抑制化合物，式（I）的化合物和式（VI）的化合物。 本发明的血管发生抑制剂抑制活组织中血管的新形成，可以用作与伤口愈合，炎症，肿瘤生长等有关的血管生成的优异治疗或预防剂。 和血管生成，如糖尿病视网膜病变，早产儿视网膜病变，视网膜静脉闭塞，老年性盘状黄斑变性等，以及用于预防肿瘤转移。

    Angiogenesis inhibitor
    9.
    发明授权
    Angiogenesis inhibitor 失效
    血管生成抑制剂

    公开(公告)号：US06551999B1

    公开(公告)日：2003-04-22

    申请号：US09243822

    申请日：1999-02-03

    申请人： Chiho Fukiage ,  Mitsuyoshi Azuma ,  Jun Inoue ,  Masayuki Nakamura ,  Yuka Yoshida

    发明人： Chiho Fukiage ,  Mitsuyoshi Azuma ,  Jun Inoue ,  Masayuki Nakamura ,  Yuka Yoshida

    IPC分类号： C07K506

    CPC分类号： A61K38/55 ,  C07C311/19 ,  C07D303/48

    摘要： An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) and compounds of the formula (VI) can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

    摘要翻译： 一种包含半胱氨酸蛋白酶抑制化合物的血管生成抑制剂。 作为优选的半胱氨酸蛋白酶抑制化合物，可以使用环氧琥珀酸化合物，肽卤代酰肼化合物，钙蛋白酶抑制化合物，式（I）的化合物和式（VI）的化合物。 本发明的血管发生抑制剂抑制活组织中血管的新形成，可以用作与伤口愈合，炎症，肿瘤生长等有关的血管生成的优异治疗或预防剂。 和血管生成，如糖尿病视网膜病变，早产儿视网膜病变，视网膜静脉闭塞，老年性盘状黄斑变性等，以及用于预防肿瘤转移。

    Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytography
    10.
    发明授权
    Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytography 失效
    用于预防和治疗眼底组织细胞病变相关疾病的药物组合物

    公开(公告)号：US06423691B1

    公开(公告)日：2002-07-23

    申请号：US09623393

    申请日：2000-09-05

    申请人： Mitsuyoshi Azuma ,  Yukuo Yoshida ,  Yuji Sakamoto ,  Jun Inoue

    发明人： Mitsuyoshi Azuma ,  Yukuo Yoshida ,  Yuji Sakamoto ,  Jun Inoue

    IPC分类号： A61K3800

    CPC分类号： A61K38/00 ,  A61K31/18

    摘要： A pharmaceutical composition for the prophylaxis and therapy of a disease arising from ocular fundus tissue cytopathy such as retinochoroidal disease, glaucoma, and posterior complication arising form photocoagulation, which contains, as an active ingredient, a compound of formula (I) wherein R1 represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which is optionally substituted; R2 and R3 may be the same or different and each represents hydrogen or an alkyl group having 1 to 4 carbon atoms or R2 and R3 may jointly form a ring having 3 to 7 carbon atoms; and R4 represents a lower alkyl group which substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 一种用于预防和治疗由眼底组织细胞病变（例如视网膜色素性疾病，青光眼和由光凝产生的后期并发症）引起的疾病的药物组合物，其包含作为活性成分的式（I）化合物，其中R 1表示 具有1至4个碳原子的烷基或任选被取代的具有6至10个碳原子的芳基; R2和R3可以相同或不同，各自表示氢或具有1-4个碳原子的烷基，或者R2和R3可以共同形成具有3至7个碳原子的环; R 4表示被芳基，环烷基或芳香杂环残基取代的低级烷基或其药学上可接受的盐。